Home

statistik Erfaren person ympning reuters teva ny G Förtäckt

Teva Pharmaceutical | PBS NewsHour
Teva Pharmaceutical | PBS NewsHour

Teva Pharmaceuticals Slashing 25% of Workforce, Suspending Dividend
Teva Pharmaceuticals Slashing 25% of Workforce, Suspending Dividend

CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports |  Ctech
CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports | Ctech

Teva rejects Israeli PM's request to keep Jerusalem plant open | Reuters
Teva rejects Israeli PM's request to keep Jerusalem plant open | Reuters

Drugmaker Teva does not see big impact on business from Israel-Hamas war |  Reuters
Drugmaker Teva does not see big impact on business from Israel-Hamas war | Reuters

Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters

Teva, armed with 2 recent launches, raises revenue guidance
Teva, armed with 2 recent launches, raises revenue guidance

Fears of Israeli job cuts at Teva sparks call for general strike | Reuters
Fears of Israeli job cuts at Teva sparks call for general strike | Reuters

US judge overturns Eli Lilly's $176.5 million loss in Teva patent case |  Reuters
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case | Reuters

Teva's $420mn investor settlement to be mostly covered by insurers | The  Insurer
Teva's $420mn investor settlement to be mostly covered by insurers | The Insurer

Teva to proceed with Rimsa breach of contract suit after ruling | Reuters
Teva to proceed with Rimsa breach of contract suit after ruling | Reuters

US court invalidates key TEVA drug patent
US court invalidates key TEVA drug patent

Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters
Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters

Teva, Texas strike opioid settlement worth $225M | Business Insurance
Teva, Texas strike opioid settlement worth $225M | Business Insurance

Teva reaches proposed $4.35 billion settlement of US opioid lawsuits | CNN  Business
Teva reaches proposed $4.35 billion settlement of US opioid lawsuits | CNN Business

PM to Teva boss: Minimize damage to workers, especially in periphery -  Israel News - The Jerusalem Post
PM to Teva boss: Minimize damage to workers, especially in periphery - Israel News - The Jerusalem Post

Biden admin urges Supreme Court to hear 'skinny labels' case between Teva,  GSK | Reuters
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK | Reuters

Teva Names Interim CEO, New Chairman As Vigodman Steps Down
Teva Names Interim CEO, New Chairman As Vigodman Steps Down

Teva to pay up to $523 million to New York state to settle opioid suit |  Business Insurance
Teva to pay up to $523 million to New York state to settle opioid suit | Business Insurance

Teva to Acquire Mexico's Rimsa for $2.3 Billion - WSJ
Teva to Acquire Mexico's Rimsa for $2.3 Billion - WSJ

Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters

Teva, Texas strike opioid settlement worth $225 million - The Jerusalem Post
Teva, Texas strike opioid settlement worth $225 million - The Jerusalem Post

California judge rules for Israeli Teva in major opioid lawsuit - The  Jerusalem Post
California judge rules for Israeli Teva in major opioid lawsuit - The Jerusalem Post

Teva Pharm to stay as unified drugmaker, sees big interest in API business,  says CEO | Reuters
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO | Reuters

Teva Pharmaceutical Is in Recovery - WSJ
Teva Pharmaceutical Is in Recovery - WSJ

Teva settles shareholder lawsuit over generic drug | Business Insurance
Teva settles shareholder lawsuit over generic drug | Business Insurance

Drug-maker Teva fueled opioid addiction in NY, jury finds | Business  Insurance
Drug-maker Teva fueled opioid addiction in NY, jury finds | Business Insurance

Mylan's Chairman was Right | Ctech
Mylan's Chairman was Right | Ctech